JP2021534129A5 - - Google Patents
Info
- Publication number
- JP2021534129A5 JP2021534129A5 JP2021506964A JP2021506964A JP2021534129A5 JP 2021534129 A5 JP2021534129 A5 JP 2021534129A5 JP 2021506964 A JP2021506964 A JP 2021506964A JP 2021506964 A JP2021506964 A JP 2021506964A JP 2021534129 A5 JP2021534129 A5 JP 2021534129A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- inhibitor
- combination according
- ret
- patient
- Prior art date
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862717480P | 2018-08-10 | 2018-08-10 | |
| US62/717,480 | 2018-08-10 | ||
| US201862735730P | 2018-09-24 | 2018-09-24 | |
| US62/735,730 | 2018-09-24 | ||
| PCT/US2019/045919 WO2020033838A2 (en) | 2018-08-10 | 2019-08-09 | Treatment of egfr-mutant cancer |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021534129A JP2021534129A (ja) | 2021-12-09 |
| JPWO2020033838A5 JPWO2020033838A5 (https=) | 2022-08-17 |
| JP2021534129A5 true JP2021534129A5 (https=) | 2022-08-17 |
| JP7490635B2 JP7490635B2 (ja) | 2024-05-27 |
Family
ID=69415686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021506964A Active JP7490635B2 (ja) | 2018-08-10 | 2019-08-09 | Ｅｇｆｒ変異がんの処置 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210308134A1 (https=) |
| EP (1) | EP3833372A4 (https=) |
| JP (1) | JP7490635B2 (https=) |
| CN (1) | CN112703014A (https=) |
| WO (1) | WO2020033838A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| PL3371171T3 (pl) | 2015-11-02 | 2024-03-25 | Blueprint Medicines Corporation | Inhibitory RET |
| SI3773589T1 (sl) | 2018-04-03 | 2024-03-29 | Blueprint Medicines Corporation | Inhibitor RET za uporabo pri zdravljenju raka, ki ima RET spremembo |
| JP2023527412A (ja) | 2020-05-29 | 2023-06-28 | ブループリント メディシンズ コーポレイション | プラルセチニブの固体形態 |
| JP2023501757A (ja) * | 2020-05-29 | 2023-01-18 | ブループリント メディシンズ コーポレイション | プラルセチニブ薬学的組成物 |
| WO2022046867A1 (en) * | 2020-08-25 | 2022-03-03 | Loxo Oncology, Inc. | Osimertinib and selpercatinib combinations for the treatment of egfr- and ret-associated cancers |
| CN116867492A (zh) * | 2020-11-20 | 2023-10-10 | 赫尔森保健股份公司 | 使用4-氨基-n-[4-(甲氧基甲基)苯基]-7-(1-甲基环丙基)-6-(3-吗啉代丙-1-炔-1-基)-7h-吡咯并[2,3-d]嘧啶-5-羧酰胺治疗肿瘤的方法 |
| EP4323356A1 (en) | 2021-04-13 | 2024-02-21 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| CN113143931A (zh) * | 2021-04-16 | 2021-07-23 | 南方医科大学 | 甲磺酸奥西替尼在制备寻常型银屑病治疗药物中的应用 |
| CN116440136B (zh) * | 2023-04-17 | 2024-02-09 | 浙江大学智能创新药物研究院 | 甲磺酸阿美替尼在制备治疗乐伐替尼心脏毒性药物中的应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2550361C (en) | 2003-12-19 | 2014-04-29 | Prabha Ibrahim | Compounds and methods for development of ret modulators |
| US20090227598A1 (en) | 2006-01-24 | 2009-09-10 | Buser-Doepner Carolyn A | Ret Tyrosine Kinase Inhibition |
| US20090012045A1 (en) | 2007-06-26 | 2009-01-08 | Rigel Pharmaceuticals, Inc. | Methods of Treating Cell Proliferative Disorders |
| WO2009100536A1 (en) | 2008-02-15 | 2009-08-20 | Methylgene Inc. | Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures |
| EP2740742B1 (en) | 2011-08-04 | 2018-03-14 | National Cancer Center | Fusion gene of kif5b gene and ret gene, and method for determining effectiveness of cancer treatment targeting fusion gene |
| EP3564261B1 (en) | 2011-08-23 | 2024-11-13 | Foundation Medicine, Inc. | Kif5b-ret fusion molecules and uses thereof |
| MX370814B (es) * | 2011-09-02 | 2020-01-08 | Univ California | Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas. |
| JP2015109806A (ja) | 2012-03-22 | 2015-06-18 | アステラス製薬株式会社 | 新規ｒｅｔ融合体の検出法 |
| US20150177246A1 (en) | 2012-07-26 | 2015-06-25 | Lsip, Llc | Fusion gene of cep55 gene and ret gene |
| US20150057335A1 (en) | 2013-08-20 | 2015-02-26 | National Cancer Center | Novel fusion genes identified in lung cancer |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| BR112018000808A2 (pt) | 2015-07-16 | 2018-09-04 | Array Biopharma Inc | compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase |
| CN105255927B (zh) | 2015-09-30 | 2018-07-27 | 温州医科大学附属第一医院 | 一种kiaa1217-ret融合基因 |
| PL3371171T3 (pl) | 2015-11-02 | 2024-03-25 | Blueprint Medicines Corporation | Inhibitory RET |
| JP2018536682A (ja) | 2015-12-11 | 2018-12-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｅｇｆｒ及び／またはｅｒｂｂ３遮断に耐性のある腫瘍の成長を低減または防止するための方法 |
| TW201738228A (zh) | 2016-03-17 | 2017-11-01 | 藍圖醫藥公司 | Ｒｅｔ之抑制劑 |
| AU2017241837B2 (en) * | 2016-04-01 | 2021-07-22 | Signal Pharmaceuticals, Llc | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
| US11168090B2 (en) | 2017-01-18 | 2021-11-09 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| GB201705971D0 (en) | 2017-04-13 | 2017-05-31 | Cancer Res Tech Ltd | Inhibitor compounds |
| US10934300B2 (en) | 2017-06-23 | 2021-03-02 | San Diego State University (Sdsu) Foundation | Atropisomerism for enhanced kinase inhibitor selectivity |
| CN109180677A (zh) | 2017-06-30 | 2019-01-11 | 厦门大学 | 取代芳基醚类化合物、其制备方法、药用组合物及其应用 |
| EP3649260B1 (en) | 2017-07-07 | 2022-05-11 | Nipd Genetics Public Company Limited | Target-enriched multiplexed parallel analysis for assessment of tumor biomarkers |
| LT3728271T (lt) | 2017-12-19 | 2022-12-12 | Turning Point Therapeutics, Inc. | Makrocikliniai junginiai, skirti ligų gydymui |
| WO2019143991A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS |
| CN111615514B (zh) | 2018-01-18 | 2022-10-11 | 奥瑞生物药品公司 | 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物 |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
-
2019
- 2019-08-09 WO PCT/US2019/045919 patent/WO2020033838A2/en not_active Ceased
- 2019-08-09 EP EP19847106.2A patent/EP3833372A4/en not_active Withdrawn
- 2019-08-09 CN CN201980060618.8A patent/CN112703014A/zh active Pending
- 2019-08-09 JP JP2021506964A patent/JP7490635B2/ja active Active
- 2019-08-09 US US17/267,149 patent/US20210308134A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021534129A5 (https=) | ||
| Kim et al. | Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor | |
| JP7304629B2 (ja) | 突然変異ｒａｓペプチド及び化学療法剤を含むペプチドワクチン | |
| MA30967B1 (fr) | Sels et formes cristallines de 2-methyl-2-methyl-2-[4-(3-methyl-2-oxo-8-quinolein-3-yl-2,3-dihydro-imidazo[4,5-c]quinolein-1-yl) - phenyl]-propionitrile. | |
| JP2017533963A5 (https=) | ||
| IL255312B (en) | Therapeutic and diagnostic methods for cancer containing a pd–l1 binding antagonist | |
| JP2014506321A5 (https=) | ||
| US20240229156A1 (en) | Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles | |
| JP2013507415A5 (https=) | ||
| JP2017529382A5 (https=) | ||
| JP2016525097A5 (https=) | ||
| RU2017119066A (ru) | Композии апилимода и способы их применения в лечении колоректального рака | |
| JP2024533423A (ja) | 薬学的組成物およびその使用 | |
| TW202332444A (zh) | 用於治療癌症之醫藥組成物 | |
| WO2023114984A1 (en) | Tead inhibitors and uses thereof | |
| JPWO2020033838A5 (https=) | ||
| WO2023235716A2 (en) | Cancer treatment using topoisomerase i inhibitors and plk1 inhibitors | |
| JP2019524888A (ja) | 血液がんの治療のためのＰＰＡＲγアゴニスト | |
| JP2018522049A5 (https=) | ||
| Ohno | Treatment of chronic myeloid leukemia with imatinib mesylate | |
| US20240350500A1 (en) | Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer | |
| WO2021055846A1 (en) | Methods and compositions for treating myc-driven cancers | |
| CN119604291A (zh) | Blu-945联合奥斯替尼治疗非小细胞肺癌 | |
| JPWO2022246459A5 (https=) | ||
| EP3236966B1 (en) | Combination of raf inhibitors and taxanes |